Trastuzumab injection 150mg Canmab
Trade Name: Canmab
Manufacturer: Biocon
Presentation: Injection
Strength: 150mg
What is a Trastuzumab injection of 150mg?
Trastuzumab injection 150mg is a drug that is used to treat cancers of the breast, stomach, and oesophagus. This medicine is used to treat cancers that produce an excessive amount of a chemical known as HER2 protein. Trastuzumab is a monoclonal antibody, which means it belongs to a class of drugs called monoclonal antibodies.
What is trastuzumab used for?
Trastuzumab, also known as Herceptin, Herzuma, and Ontruzant, is a cancer medication with a specific target. It is used to treat early and advanced breast cancer, advanced stomach cancer, and cancer of the junction between the food pipe and the stomach (gastro-oesophageal junction).
How effective is trastuzumab?
A 2014 study of almost 4000 patients found that adding trastuzumab to chemotherapy increased 10-year survival from 75.2 percent to 84 percent, resulting in a 37 percent relative improvement in overall survival. The disease-free survival rate climbed from 62.2 percent to 73.7 percent over a 10-year period. All patient groupings reaped the benefits.
How long do you take trastuzumab?
Trastuzumab is commonly administered for one year following surgery if you have primary breast cancer (around 18 cycles). If you’re on trastuzumab before surgery, expect to go through four to six cycles.
Does trastuzumab cause hair loss?
Is it true that I’ll lose my hair if I take trastuzumab? Hair loss is not a common side effect of trastuzumab treatment. If you receive trastuzumab with chemotherapy, you may develop hair loss as a side effect of the chemotherapy.
Is trastuzumab chemotherapy?
Trastuzumab is a monoclonal antibody that is used to treat metastatic (spread) breast cancer. It works against cancers that have an overabundance of the HER2/neu protein. As part of an adjuvant chemotherapy regimen for lymph-node-positive, HER2/neu protein-positive breast cancer patients. To know more click here.
Is trastuzumab immunotherapy?
Theratope is active selective immunotherapy, whereas trastuzumab is passive immunotherapy that targets the HER-2 receptor (Herceptin). Trastuzumab has been shown to be effective in HER-2-overexpressing metastatic breast cancer as a monotherapy and in combination with chemotherapy treatments.
Why is trastuzumab given after chemotherapy?
to treat metastatic HER2-positive breast cancer in order to halt its progression to treat HER2-positive breast cancer in its early stages, either as part of a chemotherapy regimen or as a stand-alone treatment after a chemotherapy regimen that includes an anthracycline, to lower the likelihood of the cancer returning (recurrence).
We are a Global wholesaler and exporter from India and operate in more than 5 countries like Oman, Qatar, UAE, Saudi, Myanmar. If you’re looking for a different product or brand, click here.